A groundbreaking achievement in brain-computer interface technology: an ALS patient uses a Neuralink implant to edit and narrate a YouTube video.

The third patient of Elon Musk's brain computer interface company Neuralink is using the billionaire's foul-mouthed AI ...

Alchemab Therapeutics, whose labs are in Cambridge UK, stands to scoop $415 million from Eli Lilly and Company following a ...

Interestingly, Smith is the first non-verbal individual and only the third person globally to receive a Neuralink Brain-Chip ...

The approved ALS therapy Radicava may cause serious unexpected side effects, such as liver problems and blood clots, per U.S. FDA data.

Clene’s cash and cash equivalents totaled $9.8 million as of March 31, 2025, compared to $12.2 million as of December 31, 2024. Clene expects that its resources as of March 31, 2025, will be ...

Prilenia, Ferrer entered collaboration agreement for commercialization and co-development of pridopidine in Europe and other ...

The deal builds on an existing research collaboration between Eli Lilly and Alchemab to discover new ALS drugs.

Houston mortgage duo Cissy and Christopher Larkin are channeling a four-year ALS battle into a widespread fundraiser.

Lilly licenses Alchemab’s ALS antibody ATLX-1282 in $415mn deal, expanding its neuroscience pipeline with a novel, ...

Learn more about whether argenx SE or Exact Sciences Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Eli Lilly (LLY) inks a licensing agreement with Alchemab to jointly develop an ALS drug in a $415M deal. Read more here.